KLRS Insider Trading Activity and SEC Form 4 Filings
KLRS insider trading summary
Over the past 12 months, insiders at Kalaris Therapeutics, Inc. (KLRS) reported 5 open-market purchases worth $25.0M by 5 insiders and 1 sale worth $13K by 1 insider on SEC Form 4. Net insider buying was $25.0M.
Latest KLRS insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Mar 20, 2026 | Brett R Hagen | Chief Accounting Officer | Sell | $13K (1,915 @ $6.72) |
| Dec 18, 2025 | Srinivas Akkaraju | Insider | Buy | $5.0M (479,847 @ $10.42) |
| Dec 18, 2025 | Samsara BioCapital, L.P. | 10% Owner | Buy | $5.0M (479,847 @ $10.42) |
| Dec 18, 2025 | Samsara Opportunity Fund, L.P. | 10% Owner | Buy | $5.0M (479,847 @ $10.42) |
| Dec 18, 2025 | Samsara Opportunity Fund GP, LLC | 10% Owner | Buy | $5.0M (479,847 @ $10.42) |
| Dec 18, 2025 | Samsara BioCapital GP, LLC | 10% Owner | Buy | $5.0M (479,847 @ $10.42) |
| Mar 26, 2025 | Brett R Hagen | Chief Accounting Officer | Sell | $8K (907 @ $8.97) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.